Skip to content
Krishna Institute of Medical Sciences logo

Krishna Institute of Medical Sciences

KIMS NSE
₹740.55 No trade today
P/E
146.64
View as Markdown
MCP
Close 4 Nov 2026 ₹740.55 +20.25 +2.81% 1Y
Start ₹720.30

Key Fundamentals

SmallcapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
9.50%
Debt to Equity
1.89
EPS (TTM)
₹5.05
Book Value
₹89.22
Market Cap
—
P/E (TTM)
146.64
P/B
8.30
ROE
11.30%
Dividend Yield
0.00%
EBITDA
₹828 Cr
52W High
₹858.00
52W Low
₹575.80
Volume
0

Peer Comparison

Healthcare › Healthcare Services › Hospitals › Hospital

Krishna Institute of Medical Sciences peer comparison
Apollo Hospitals
₹8,599.5059.18₹1,22,850 Cr13.040.24%21.20%17.40%₹26,430 Cr₹2,171 Cr
Max Healthcare Institute
₹927.1561.89₹89,301 Cr7.960.22%14.70%14.70%₹8,712 Cr₹1,457 Cr
Manipal Health Enterprises
₹667.2088.96₹86,479 Cr5.340.00%6.64%8.30%₹11,400 Cr₹906 Cr
Aster DM Healthcare
₹719.55117.00₹59,927 Cr14.910.44%11.30%11.60%₹4,876 Cr₹363 Cr
Fortis Healthcare
₹790.6556.96₹59,706 Cr6.030.13%11.20%13.40%₹9,506 Cr₹1,070 Cr
Narayana Hrudayalaya
₹1,931.5048.36₹39,090 Cr7.890.24%20.50%15.50%₹9,072 Cr₹816 Cr
Global Health
₹1,402.0067.76₹37,618 Cr9.520.04%15.20%17.40%₹4,683 Cr₹552 Cr
Krishna Institute of Medical Sciences (this company)
₹740.55146.64₹30,912 Cr8.300.00%11.30%9.50%₹4,212 Cr₹194 Cr
Median 8 companies₹858.9064.83₹59,817 Cr8.130.18%13.00%14.05%₹8,892 Cr₹861 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

40 Weak

Data confidence 100/100

Category scores

Quality
53
Average
Returns, margins, earnings quality 22% weight
Valuation
17
Poor
Cheap vs sector & own history 24% weight
Growth
89
Strong
Sales & profit trajectory 9% weight
Financial Health
15
Poor
Solvency, leverage, coverage 9% weight
Momentum
20
Poor
Trend strength, vol-adjusted 12% weight
Ownership
60
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is expected to give good quarter
  • Company's median sales growth is 21.9% of last 10 years

Weaknesses

4
  • Stock is trading at 12.5 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -1.62%
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish5311
OscillatorsNeutral333
Moving AveragesStrong Bullish208

Key readings

RSI (14)
60.74
Neutral
MACD (12,26,9)
−5.22
Bullish
SMA (50)
737.98
Bullish
SMA (200)
727.02
Bullish

As of

Analyst Rating

Based on 14 analysts
BUY93%

13 of 14 analysts rate Buy, 0 Hold, 1 Sell.

As of

BUY
13
93%
HOLD
0
0%
SELL
1
7%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+22.53%
5Y+24.04%
3Y+21.11%
1Y+28.67%
TTM+30.95%

Net profit

Net profit growth by window
10Y+24.07%
5Y+3.37%
3Y−12.88%
1Y−41.69%
TTM−51.98%

Operating cash flow

Operating cash flow growth by window
10Y+18.32%
5Y+7.50%
3Y+5.76%
1Y−12.20%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−0.42 pp
5Y−7.48 pp
3Y−6.93 pp
1Y−5.26 pp
TTM−5.00 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹567 Cr
Mar 2018₹664 Cr
Mar 2019₹918 Cr
Mar 2020₹1,123 Cr
Mar 2021₹1,330 Cr
Mar 2022₹1,651 Cr
Mar 2023₹2,198 Cr
Mar 2024₹2,498 Cr
Mar 2025₹3,035 Cr
Mar 2026₹3,905 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹33.00 Cr
Mar 2018−₹46.00 Cr
Mar 2019−₹49.00 Cr
Mar 2020₹115 Cr
Mar 2021₹205 Cr
Mar 2022₹344 Cr
Mar 2023₹366 Cr
Mar 2024₹336 Cr
Mar 2025₹415 Cr
Mar 2026₹242 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹265 Cr +9.9% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 3 Nov 2026
AI opinion · based on fundamentals
Risk high

Krishna Institute of Medical Sciences Ltd trades at ₹730.5 as of 2026-11-03 with a market cap of ₹30,662.57 crore and a trailing PE of 144.65. The company shows strong long-term revenue compounding at 23% over 10 years but TTM profit has declined 43%, creating a sharp divergence between top-line momentum and bottom-line performance.

Bull Case 8
  • Compounded sales growth of 23% over 10 years and 24% over 5 years reflects a durable, long-term revenue expansion track record in a structurally growing healthcare services market
  • TTM revenue growth has accelerated to 31%, outpacing even the strong 10-year and 5-year sales CAGR, suggesting the company is gaining market share or expanding capacity effectively
  • Median sales growth of 21.9% over the last 10 years indicates consistency in top-line delivery rather than lumpy or one-off revenue gains
  • 10-year compounded profit growth of 25% demonstrates the company has historically been able to convert revenue growth into earnings growth over full cycles
  • 5-year stock CAGR of 25% and 3-year stock CAGR of 22% show the market has rewarded the company's growth trajectory over medium-term horizons
  • 10-year average ROE of 18% and 5-year average ROE of 18% indicate the business has historically generated attractive returns on shareholder equity
  • The stock trades 14.8% below its 52-week high of ₹858, and the company is expected to deliver a good upcoming quarter, which could serve as a near-term catalyst
  • The stock is 26.9% above its 52-week low of ₹575.8, suggesting it has maintained a recovery trend from its lows
Bear Case 8
  • TTM profit has declined 43%, a severe contraction that stands in stark contrast to the 31% TTM revenue growth and signals major margin compression or exceptional charges
  • Trailing PE of 144.65 is extremely elevated, implying the market is pricing in a sharp earnings recovery that may not materialize, leaving significant downside risk if profits do not rebound
  • 3-year compounded profit growth is negative at -9%, indicating the earnings deterioration is not a single-quarter event but a multi-year trend
  • Debt-to-equity ratio of 1.89 is relatively high for a healthcare services company, and there are indications the company might be capitalizing interest costs, which could mask the true cost of leverage in reported profits
  • ROE has deteriorated from 18% on a 5-year average to 11% in the last year and 9.46% currently, showing a clear downward trend in capital efficiency
  • The company pays zero dividend despite reporting repeated profits, offering no cash return to shareholders while trading at a price-to-book ratio of 8.19
  • Promoter holding decreased by 1.62% over the last quarter, which may signal reduced insider confidence at current valuations
  • The stock trades at 12.5 times book value, a premium that demands sustained high-growth execution and leaves little room for operational missteps

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: KIMS is in active expansion mode, doubling capacity at Anantapur, pursuing inorganic growth via the Insignia and Splendid deals, and adding asset-light O&M revenue through the Kakinada agreement. No material headwinds surfaced in recent news. The consistent focus on capacity addition and acquisition pipeline across Andhra Pradesh signals a growth-oriented trajectory heading into FY26.

Positives 3
  • Anantapur hospital doubles to 500 beds Nov 1

    KIMS Saveera Hospital in Anantapur expanded from 250 to 500 beds, adding a dedicated Oncology Block with HD-LINAC and Digital PET-CT, plus a Mother & Child Block with NICU. Group total bed strength now stands at 9,117.

  • 51% stake in Insignia Healthcare Oct 6

    Board approved acquiring up to 51% equity in Insignia Healthcare Private Limited, a hospital operator with ₹104.5 crore FY25 turnover.

  • Kakinada O&M deal signed Nov 1

    KIMS entered an Operations & Management agreement with Sarvottam Health Care to manage its Kakinada hospital, earning a 9% revenue fee on net revenue for an initial five-year term extendable by five more years.

Neutral 1
  • 22% stake in Splendid Hospitals Oct 6

    Board approved acquiring up to 22% equity in Splendid Hospitals for ₹40 crore via primary infusion. The target is an O&M entity with a modest FY26 turnover of ₹1.39 crore.

Quarterly Results

₹ Cr
KIMS quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
606
652
606
634
688
777
772
797
872
961
998
1,075
1,180
Expenses
449
475
459
475
509
559
585
599
679
757
799
868
956
Operating Profit
157
177
147
159
179
218
187
198
193
204
199
206
223
OPM %
26%
27%
24%
25%
26%
28%
24%
25%
22%
21%
20%
19%
19%
Other Income
3
3
3
4
5
5
18
15
7
4
5
1
17
Interest
9
9
12
16
18
20
26
27
33
45
57
68
83
Depreciation
32
33
35
46
39
41
45
53
53
66
79
85
101
PBT
119
139
103
100
127
162
135
134
114
97
69
55
57
Tax %
27%
27%
25%
28%
25%
26%
31%
21%
25%
26%
24%
40%
34%
Net Profit
87
101
77
71.49
95
121
92
106
85
72
52
33
37
EPS (₹)
2.02
2.3
1.8
1.64
2.16
2.68
2.22
2.54
1.96
1.67
1.33
1.06
0.99

Profit & Loss

₹ Cr
KIMS profit and loss, annual, ₹ crore
Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
512
567
664
918
1,123
1,330
1,651
2,198
2,498
3,035
3,905
4,212
Expenses
403
450
593
833
872
953
1,126
1,587
1,850
2,242
3,090
3,380
Operating Profit
109
118
71
85
251
377
524
611
648
793
815
833
OPM %
21%
21%
11%
9%
22%
28%
32%
28%
26%
26%
21%
20%
Other Income
5
3
37
6
5
9
27
41
13
43
17
28
Interest
37
32
88
49
44
37
22
37
55
100
215
253
Depreciation
36
35
40
56
71
70
73
129
147
177
283
331
PBT
41
53
−20
−15
141
279
457
485
460
558
334
277
Tax %
32%
37%
126%
223%
18%
26%
25%
25%
27%
26%
28%
—
Net Profit
28
33
−46
−49
115
205
344
366
336
415
242
194
EPS (₹)
0.76
0.91
−1.32
−1.28
3.2
5.19
8.32
8.41
7.75
9.61
6.03
5.05
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
KIMS balance sheet, annual, ₹ crore
Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
70
72
50
74
74
78
80
80
80
80
80
Reserves
193
255
−209
466
524
786
1,307
1,590
1,748
2,058
2,167
Borrowings
256
280
753
336
369
316
257
678
1,355
2,562
4,253
Other Liabilities
146
167
359
237
228
253
260
553
636
990
1,190
Total Liabilities
665
774
954
1,114
1,194
1,433
1,904
2,901
3,820
5,689
7,691
Fixed Assets
515
518
755
863
916
931
1,005
1,766
2,434
3,348
5,710
CWIP
2
64
0
0
2
9
21
477
600
1,214
606
Investments
11
14
0
0
0
0
332
68
157
99
103
Other Assets
137
177
199
250
276
493
546
590
629
1,028
1,271
Total Assets
665
774
954
1,114
1,194
1,433
1,904
2,901
3,820
5,689
7,691

Cash Flow

₹ Cr
KIMS cash flow, annual, ₹ crore
Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
95
82
106
134
202
356
324
432
521
582
511
Investing
−41
−100
−64
−110
−125
−354
−412
−416
−753
−1,116
−1,452
Financing
−65
24
−39
−27
−44
10
61
20
217
543
940
Net Cash Flow
−11
5
3
−3
32
12
−26
36
−15
9
−1
Free Cash Flow
61
−18
49
57
150
262
154
−140
−125
−380
−902
CFO/OP
88
80
192
195
102
104
86
87
102
91
81

Ratios

KIMS financial ratios, annual
Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
47
59
59
49
43
30
28
42
43
48
52
Inventory Days
36
43
46
47
44
30
37
—
—
—
—
Days Payable
194
207
215
181
177
167
133
—
—
—
—
Cash Conversion Cycle
−111
−105
−110
−85
−91
−106
−67
42
43
48
52
Working Capital Days
11
26
−333
−15
−15
−31
−3
8
−5
−29
−37
ROCE %
—
15%
11%
5%
20%
29%
34%
24%
17%
15%
10%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Krishna Institute of Medical Sciences insights

66 extracted metrics across FY05–FY27.

Shareholding Pattern

As of Sep 2026

  • DIIs 33.22%
  • Promoters 32.66%
  • FIIs 15.01%
  • Public 11.83%
  • Others 7.28%

11.71% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Krishna Institute of Medical Sciences

What does Krishna Institute of Medical Sciences Ltd do?
Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered.
Where is Krishna Institute of Medical Sciences Ltd (KIMS) listed?
Krishna Institute of Medical Sciences Ltd trades as KIMS on the NSE and under code 543308 on the BSE.
Which sector does Krishna Institute of Medical Sciences Ltd belong to?
Krishna Institute of Medical Sciences Ltd is classified under the Healthcare Services sector, in the Hospitals industry.
What is the PE ratio of Krishna Institute of Medical Sciences Ltd?
Krishna Institute of Medical Sciences Ltd trades at a PE ratio of 146.64 as of 4 Nov 2026, on earnings per share of ₹5.05, against a book value of ₹89.22 per share.
What is the 52-week high and low of Krishna Institute of Medical Sciences Ltd?
Over the last 52 weeks Krishna Institute of Medical Sciences Ltd has traded between ₹575.8 and ₹858 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Krishna Institute of Medical Sciences Ltd?
Krishna Institute of Medical Sciences Ltd reported a return on equity of 11.30%. Its debt-to-equity ratio is 1.89.

Company Information

Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and an additional quaternary healthcare facility in tier-1 cities.

Website kimshospitals.com
Listed 28 Jun 2021
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/KIMS.md for Krishna Institute of Medical Sciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month